Stock 002252 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai RAAS Blood Products Co., Ltd.

Equities

002252

CNE100000C31

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-07-04 EDT 		5-day change 1st Jan Change
7.67 CNY +0.13% Intraday chart for Shanghai RAAS Blood Products Co., Ltd. -1.92% -4.12%
06-20 Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products MT
06-19 RAAS Blood Products Renews Cooperation Deal With Spain's Grifols MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. Stock Shanghai RAAS Blood Products Co., Ltd.
-4.12% 6.96B
C-
CSL LIMITED Stock CSL Limited
+4.57% 96.72B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+5.66% 41.43B
A-
BIOGEN INC. Stock Biogen Inc.
-12.80% 32.7B
B-
UCB Stock UCB
+80.99% 29.06B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.53% 15.38B
C
INCYTE CORPORATION Stock Incyte Corporation
-8.70% 12.97B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.22% 11.36B
D+
ALTEOGEN INC. Stock ALTEOGEN Inc.
+183.25% 9.9B
D
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.60% 8.93B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 002252 Stock
  4. Ratings Shanghai RAAS Blood Products Co., Ltd.